

Toni K Choueiri

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6798379/toni-k-choueiri-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

983
papers

57,497
citations

107
h-index

221
g-index

1,099
ext. papers

75,145
ext. citations

6.7
avg, IF

7.87
L-index

#	Paper	IF	Citations
983	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1803-13	59.2	3725
982	Comprehensive molecular characterization of clear cell renal cell carcinoma. <i>Nature</i> , 2013 , 499, 43-9	50.4	2184
981	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018 , 378, 1277-1290	59.2	2064
980	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1015-1026	59.2	1788
979	The Immune Landscape of Cancer. <i>Immunity</i> , 2018 , 48, 812-830.e14	32.3	1754
978	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5794-9	2.2	1390
977	Pazopanib versus sunitinib in metastatic renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2013 , 369, 722-31	59.2	1332
976	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019 , 380, 1103-1115	59.2	1069
975	Post-acute COVID-19 syndrome. <i>Nature Medicine</i> , 2021 , 27, 601-615	50.5	976
974	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	41.8880	1918880
973	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015 , 373, 1814-23	59.2	762
972	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 135-45	59.2	753
971	Systemic Therapy for Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 354-366	59.2	641
970	Marital status and survival in patients with cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3869-76	2.2	606
969	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology, The</i> , 2013 , 14, 141-8	21.7	598
968	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015 , 5, 1164-1177	24.4	581
967	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 917-927	21.7	580

966	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018 , 359, 801-806	33.3	562
965	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018 , 24, 749-757	50.5	558
964	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , 2014 , 26, 319-330	24.3	521
963	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019 , 393, 2404-2415	40	490
962	Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 591-597	2.2	434
961	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016 , 17, 231	18.3	391
960	Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 2008-16	40	374
959	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , 2014 , 4, 1140-53	24.4	361
958	Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2280-5	2.2	346
957	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1370-1385	21.7	343
956	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2013-20	2.2	337
955	Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 181-6	2.2	336
954	Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 127-31	2.2	328
953	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016 , 29, 723-736	26.3	324
952	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 804-834	7.3	320
951	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018 , 23, 313-326.e5	10.6	295
950	Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2359-66	27.4	292
949	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , 2017 , 31, 820-832.e3	27.3	286

948	Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014 , 66, 704-10	10.2	282
947	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 829-841	59.2	280
946	Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. <i>European Urology</i> , 2014 , 66, 42-54	10.2	277
945	Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1850-5	2.2	268
944	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1289-1300	59.2	263
943	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017 , 5, 312-318	12.5	259
942	The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. <i>Journal of Urology</i> , 2011 , 185, 60-6	2.5	258
941	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018 , 50, 1271-1281	36.3	249
940	Cost implications of the rapid adoption of newer technologies for treating prostate cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1517-24	2.2	240
939	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology, The</i> , 2018 , 19, 405-415	21.7	236
938	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology, The</i> , 2015 , 16, 293-300	21.7	229
937	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , 2016 , 14, 2476-89	10.6	228
936	A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2014 , 32, 178-87	4.3	226
935	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. <i>Cancer Discovery</i> , 2014 , 4, 546-53	24.4	224
934	Congestive heart failure risk in patients with breast cancer treated with bevacizumab. <i>Journal of Clinical Oncology</i> , 2011 , 29, 632-8	2.2	222
933	Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. <i>Lancet Oncology, The</i> , 2009 , 10, 967-74	21.7	219
932	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. <i>Nature Communications</i> , 2019 , 10, 1617	17.4	218
931	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology, The</i> , 2015 , 16, 426-35	21.7	209

930	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 1097-104	6.7	206
929	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2015 , 3, 1158-64	12.5	205
928	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3916-3923	22.3	204
927	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. <i>Annals of Oncology</i> , 2015 , 26, 812-817	10.3	202
926	PD-L1 expression in nonclear-cell renal cell carcinoma. <i>Annals of Oncology</i> , 2014 , 25, 2178-2184	10.3	202
925	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. <i>European Urology</i> , 2016 , 69, 866-74	10.2	199
924	Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. <i>New England Journal of Medicine</i> , 2014 , 370, 1769-70	59.2	199
923	Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , 2007 , 110, 543-50	6.4	198
922	Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2 α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 867-874	2.2	198
921	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , 2016 , 48, 725-32	36.3	193
920	A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>European Urology</i> , 2014 , 66, 529-41	10.2	181
919	Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. <i>European Journal of Cancer</i> , 2018 , 94, 115-125	7.5	179
918	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1889-94	2.2	177
917	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. <i>Clinical Cancer Research</i> , 2015 , 21, 1071-7	12.9	173
916	von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. <i>Journal of Urology</i> , 2008 , 180, 860-5; discussion 865-6	2.5	170
915	ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. <i>European Urology</i> , 2014 , 66, 77-84	10.2	169
914	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology, The</i> , 2018 , 19, 451-460	21.7	168
913	NCCN clinical practice guidelines in oncology: kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 618-30	7.3	168

912	Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. <i>European Urology</i> , 2014 , 65, 577-84	10.2	166
911	Kidney cancer, version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 151-9	7.3	166
910	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. <i>Annals of Oncology</i> , 2019 , 30, 970-976	10.3	158
909	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 5461-5471	12.9	158
908	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , 2020 , 26, 909-918	50.5	155
907	Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. <i>Circulation</i> , 2019 , 140, 80-91	16.7	153
906	Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. <i>Cancer</i> , 2014 , 120, 1532-9	6.4	153
905	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4416-26	2.2	152
904	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 507-12	2.2	151
903	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016 , 22, 2445-2452	12.9	150
902	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017 , 72, 368-376	10.2	148
901	Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2020 , 31, 1030-1039	10.3	144
900	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013 , 119, 2999-3006	6.4	144
899	Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 871-7	2.2	144
898	Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. <i>Clinical Cancer Research</i> , 2011 , 17, 5443-50	12.9	142
897	Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1419-26	2.2	140
896	Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3450-6	2.2	140
895	Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3267-75	2.2	139

894	Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. <i>European Urology</i> , 2012 , 61, 1239-44	10.2	134
893	Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. <i>Cancer</i> , 2015 , 121, 311-9	6.4	129
892	Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma 2018 , 6, 5		129
891	Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. <i>Annals of Oncology</i> , 2006 , 17, 1766-71	10.3	121
890	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020 , 31, 1320-1335	10.3	121
889	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1278-1285	7.3	118
888	Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. <i>Annals of Oncology</i> , 2013 , 24, 1466-72	10.3	117
887	A phase I study of cabozantinib (XL184) in patients with renal cell cancer. <i>Annals of Oncology</i> , 2014 , 25, 1603-8	10.3	115
886	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2993-3001	2.2	112
885	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016 , 70, 358-64	10.2	112
884	Pazopanib: Clinical development of a potent anti-angiogenic drug. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 77, 163-71	7	111
883	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3655-3663	2.2	111
882	Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019 , 75, 100-110	10.2	111
881	Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. <i>Annals of Oncology</i> , 2011 , 22, 1404-1412	10.3	110
880	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020 , 5, e001079 ⁶		109
879	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. <i>Annals of Oncology</i> , 2012 , 23, 1549-55	10.3	108
878	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. <i>European Urology</i> , 2015 , 67, 100-110	10.2	106
877	Sunitinib rechallenge in metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010 , 116, 5400-6	6.4	106

876	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology, The</i> , 2012 , 13, 927-35	21.7	104
875	ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. <i>European Urology</i> , 2011 , 60, 684-90	10.2	100
874	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. <i>Annals of Oncology</i> , 2014 , 25, 149-54	10.3	99
873	Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. <i>Journal of Urology</i> , 2011 , 185, 439-44	2.5	98
872	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020 , 10, 40-53	24.4	98
871	Cancer-specific outcomes among young adults without health insurance. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2025-30	2.2	97
870	Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. <i>Cancer</i> , 2010 , 116, 5219-25	6.4	97
869	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. <i>Journal of Biological Chemistry</i> , 2015 , 290, 8110-20	5.4	96
868	Targeting the HIF2-VEGF axis in renal cell carcinoma. <i>Nature Medicine</i> , 2020 , 26, 1519-1530	50.5	95
867	Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. <i>Hypertension</i> , 2010 , 56, 1131-6	8.5	94
866	QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>British Journal of Cancer</i> , 2015 , 112, 296-305	8.7	92
865	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020 , 38, 629-646	24.3	92
864	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1905-12	2.2	92
863	Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. <i>European Urology</i> , 2011 , 59, 856-62	10.2	90
862	Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2019 , 5, 1631-1633	13.4	89
861	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , 2019 , 10, 4346	17.4	89
860	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015 , 194, 343-9	2.5	88
859	Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 2471-9	12.9	88

858	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. <i>European Urology</i> , 2013 , 63, 717-23	10.2	88
857	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 772-99	7.3	87
856	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , 2009 , 115, 981-7	6.4	87
855	A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. <i>Journal of Urology</i> , 2008 , 179, 906-10; discussion 910	2.5	87
854	NCCN clinical practice guidelines in oncology: testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 672-93	7.3	87
853	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017 , 123, 4346-4355	6.4	85
852	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020 , 26, 1733-1741	50.5	85
851	Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. <i>Annals of Oncology</i> , 2021 , 32, 787-800	10.3	85
850	Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. <i>JAMA Oncology</i> , 2017 , 3, 1249-1252	13.4	84
849	Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 2077-9	27.4	84
848	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 557-564	10.2	81
847	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , 2019 , 20, 581-590	21.7	81
846	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020 , 10, 1514-1527	24.4	80
845	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 852-860	2.2	79
844	Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. <i>Urology</i> , 2011 , 78, 93-8	1.6	79
843	Kidney cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9, 960-77	7.3	79
842	Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. <i>Trends in Cardiovascular Medicine</i> , 2013 , 23, 104-13	6.9	78
841	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 765-772	2.2	78

840	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 228-37	7	77
839	Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. <i>Clinical Cancer Research</i> , 2006 , 12, 6702-8	12.9	77
838	BRAF mutations in metanephric adenoma of the kidney. <i>European Urology</i> , 2012 , 62, 917-22	10.2	76
837	An overview of targeted treatments in cancer. <i>Clinical Therapeutics</i> , 2003 , 25, 2121-37	3.5	75
836	Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. <i>European Journal of Cancer</i> , 2012 , 48, 1519-24	7.5	74
835	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , 2010 , 106, 772-8	5.6	73
834	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 385, 683-694	59.2	73
833	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020 , 26, 1041-1043	50.5	72
832	Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. <i>Urology</i> , 2010 , 76, 430-4	1.6	72
831	Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. <i>Journal of Urology</i> , 2011 , 185, 116-20	2.5	70
830	Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , 2018 , 19, 1688-1698	21.7	70
829	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2015 , 51, 2580-6	7.5	69
828	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial 2020 , 8,		68
827	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1579-1587	2.2	68
826	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. <i>JAMA Oncology</i> , 2016 , 2, 500-7	13.4	67
825	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 758-765	12.5	66
824	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020 , 126, 4156-4167	6.4	66
823	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017 , 72, 483-487	10.2	65

822	The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. <i>Clinical Cancer Research</i> , 2013 , 19, 5218-26	12.9	65
821	Daptomycin-resistant <i>Enterococcus faecium</i> in a patient with acute myeloid leukemia. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 1215-6	6.4	65
820	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017 , 53, 79-97	14.4	64
819	Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011 , 117, 2637-42	6.4	64
818	Testicular cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 502-35	7.3	64
817	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , 2020 , 38, 63-70	2.2	64
816	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study 2015 , 3, 3		63
815	FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. <i>Cancer Medicine</i> , 2014 , 3, 835-44	4.8	63
814	Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment. <i>Arthritis and Rheumatology</i> , 2016 , 68, 556-7	9.5	63
813	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1285-91	2.8	62
812	Prostate cancer reactivates developmental epigenomic programs during metastatic progression. <i>Nature Genetics</i> , 2020 , 52, 790-799	36.3	62
811	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , 2016 , 70, 516-21	10.2	61
810	Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. <i>JAMA Oncology</i> , 2016 , 2, 85-93	13.4	61
809	Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2021 , 7, 458-460	13.4	61
808	Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. <i>Urology</i> , 2014 , 84, 386-92	1.6	60
807	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 78-86	12.9	60
806	Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e79-85	3.3	59
805	The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. <i>European Urology</i> , 2014 , 65, 723-30	10.2	59

804	Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 101-101	2.2	59
803	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1160-1170	7.3	59
802	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 313-319	19.4	59
801	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2014 , 40, 190-6	14.4	57
800	Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. <i>European Urology</i> , 2014 , 66, 502-9	10.2	56
799	Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. <i>European Urology</i> , 2014 , 65, 1086-92	10.2	56
798	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. <i>BJU International</i> , 2010 , 105, 1247-54	5.6	56
797	696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. <i>Annals of Oncology</i> , 2020 , 31, S1159	10.3	56
796	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , 2014 , 110, 1917-22	8.7	54
795	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , 2018 , 73, 71-78	10.2	54
794	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , 2021 , 39, 649-661.e5	24.3	54
793	Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. <i>European Urology</i> , 2015 , 67, 952-8	10.2	53
792	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , 2015 , 121, 3435-43	6.4	53
791	Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 1411-6	4	53
790	Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. <i>Journal of Urology</i> , 2007 , 178, 1901-5	2.5	53
789	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017 , 71, 204-209	10.2	52
788	Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2018 , 199, 1417-1425	2.5	52
787	Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2006 , 107, 2609-16	16.4	52

786	A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 431-431	2.2	52
785	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , 2019 , 25, 2458-2470	12.9	52
784	Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv054	9.7	51
783	Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , 2015 , 116, 358-65	5.6	51
782	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 1247-1255	13.4	51
781	Analgesic use and the risk of kidney cancer: a meta-analysis of epidemiologic studies. <i>International Journal of Cancer</i> , 2014 , 134, 384-96	7.5	51
780	Prospective evaluation of analgesic use and risk of renal cell cancer. <i>Archives of Internal Medicine</i> , 2011 , 171, 1487-93		51
779	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016 , 65, 102-8	7.5	51
778	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017 , 8, 15724	17.4	50
777	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018 , 74, 146-154	10.2	50
776	Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 311-5	3.3	50
775	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 80-9	7	49
774	Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 61-8	7.3	49
773	CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4513-4513	2.2	49
772	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018 , 74, 611-620	10.2	49
771	Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 80, 291-300	7	48
770	Inhibition of hypoxia-inducible factor-2 β in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. <i>Nature Medicine</i> , 2021 , 27, 802-805	50.5	48
769	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 663-669	8.7	48

768	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 2174-2184	12.9	47
767	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017 , 8, 84572-84578	3.3	47
766	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3529-3536	2.2	47
765	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
764	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021 ,	13.4	47
763	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. <i>Lancet Oncology</i> , 2013 , 14, 81-7	21.7	46
762	Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. <i>Current Opinion in Investigational Drugs</i> , 2008 , 9, 658-71		46
761	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013 , 8, 203-209	5	45
760	IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4505-4505	2.2	45
759	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , 2017 , 22, 286-292	5.7	44
758	Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3431-8	2.2	44
757	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016 , 4, 820-822	12.5	44
756	Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 199-214	19.4	44
755	Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). <i>BJU International</i> , 2014 , 113, E67-74	5.6	43
754	Kidney cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 175-82	7.3	43
753	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. <i>European Urology</i> , 2012 , 61, 307-16	10.2	43
752	Elicitation of health state utilities in metastatic renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2010 , 26, 1091-6	2.5	43
751	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018 , 6, 402-408	12.5	42

750	Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018 , 4, 225-229	13.4	42
749	Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2016 , 4, 12-7	12.5	42
748	The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act. <i>Prostate Cancer and Prostatic Diseases</i> , 2014 , 17, 273-9	6.2	42
747	10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. <i>Oncologist</i> , 2014 , 19, 507-14	5.7	42
746	Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2013 , 19, 316-23	2.2	42
745	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. <i>BJU International</i> , 2011 , 108, 1279-83	5.6	42
744	Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2007 , 18, 249-55	10.3	42
743	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , 2021 , 39, 632-648.e8	24.3	42
742	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018 , 73, 374-382	10.2	42
741	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 18.e7-18.e13	2.8	41
740	NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011 , 9 Suppl 1, S1-29	7.3	41
739	Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. <i>Prostate</i> , 2011 , 71, 1189-97	4.2	41
738	Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018790253	2.2	41
737	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 277-82	2.5	40
736	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. <i>Cancer</i> , 2012 , 118, 4777-84	6.4	40
735	Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 444-54		40
734	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019 , 76, 861-867	10.2	39
733	Mental health outcomes in elderly men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1333-40	2.8	39

732	Refusal of curative radiation therapy and surgery among patients with cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 756-64	4	39
731	Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. <i>Oncotarget</i> , 2016 , 7, 29901-15	3.3	39
730	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018 , 24, 1805-1815	12.9	38
729	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , 2016 , 6, 27702	4.9	38
728	The influence of marital status on the use of breast, cervical, and colorectal cancer screening. <i>Preventive Medicine</i> , 2016 , 89, 140-145	4.3	38
727	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 1873-83	12.9	38
726	The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. <i>PLoS Medicine</i> , 2019 , 16, e1002724	11.6	38
725	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2018 , 124, 3677-3683	6.4	38
724	Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e189-95	3.3	37
723	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1788-93	2.8	37
722	Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. <i>Journal of Clinical Oncology</i> , 2012 , 30, e264-8	2.2	37
721	Patterns of care for radical prostatectomy in the United States from 2003 to 2005. <i>Journal of Urology</i> , 2008 , 180, 1969-74	2.5	37
720	Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 907-910	5.3	37
719	Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2020 , 6, 1606-1610	13.4	36
718	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016 , 118, 95-101	5.6	36
717	Adrenocortical carcinoma: the management of metastatic disease. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 123-32	7	36
716	Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. <i>Cancer</i> , 2014 , 120, 711-21	6.4	36
715	Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. <i>Acta Oncologica</i> , 2013 , 52, 1202-12	3.2	36

714	Role of aromatase inhibitors in the treatment of breast cancer. <i>Clinical Therapeutics</i> , 2004 , 26, 1199-2143,5	36
713	Comparative effectiveness of robot-assisted vs. open radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 88.e1-88.e9	2.8 35
712	Pan-urologic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017 , 8, 199	17.4 35
711	Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. <i>European Urology</i> , 2015 , 68, 32-9	10.2 35
710	Haematologic toxicities associated with the addition of bevacizumab in cancer patients. <i>European Journal of Cancer</i> , 2011 , 47, 1161-74	7.5 35
709	Risk of bilateral renal cell cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3737-41	2.2 35
708	Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020 , 3, 372-381	6.7 35
707	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma 2020 , 8,	35
706	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. <i>European Urology Oncology</i> , 2018 , 1, 83-90	6.7 34
705	Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. <i>Acta Haematologica</i> , 2007 , 117, 162-7	2.7 34
704	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019 , 25, 6080-6088	12.9 33
703	PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. <i>Cancer Immunology Research</i> , 2014 , 2, 1132-41	12.5 33
702	The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. <i>Breast Journal</i> , 2007 , 13, 130-9	1.2 33
701	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 757-764	2.2 33
700	RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. <i>Molecular Cancer Research</i> , 2015 , 13, 130-7	6.6 32
699	Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 828-35	4 32
698	IL-8 and cancer prognosis on immunotherapy. <i>Nature Medicine</i> , 2020 , 26, 650-651	50.5 32
697	The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. <i>Seminars in Oncology</i> , 2006 , 33, 596-606	5.5 32

696	Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1. <i>Oncogenesis</i> , 2019 , 8, 7	6.6	32
695	Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. <i>Current Urology Reports</i> , 2017 , 18, 15	2.9	31
694	Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 496.e11-6	2.8	31
693	HER2 as a target in invasive urothelial carcinoma. <i>Cancer Medicine</i> , 2015 , 4, 844-52	4.8	31
692	Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. <i>Urology</i> , 2011 , 77, 402-6	1.6	31
691	Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. <i>Annals of Oncology</i> , 2006 , 17, 860-5	10.3	31
690	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , 2016 , 2, 204-209	5.1	30
689	Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1131-8	7.3	30
688	Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. <i>Drugs</i> , 2013 , 73, 1417-30	12.1	30
687	Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 645-53	4.1	30
686	Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. <i>Cancer</i> , 2010 , 116, 1887-92	6.4	30
685	Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , 2016 , 118, 286-97	5.6	30
684	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. <i>Annals of Oncology</i> , 2017 , 28, 1098-1104	10.3	29
683	The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer. <i>Cancer Cell</i> , 2020 , 37, 738-741	24.3	29
682	Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. <i>European Urology</i> , 2018 , 73, 452-461	10.2	29
681	Statins and survival outcomes in patients with metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 52, 155-62	7.5	29
680	Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. <i>Journal of Urology</i> , 2016 , 196, 1090-5	2.5	29
679	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. <i>European Journal of Cancer</i> , 2011 , 47, 2706-14	7.5	29

678	Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008 , 113, 1309-14	6.4	29
677	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 125-136	6.2	29
676	Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>European Urology</i> , 2019 , 75, 552-555	10.2	29
675	Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018792531	7.9	29
674	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders 2018 , 6, 159		29
673	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017 , 6, 902-909	7.1	28
672	Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. <i>European Urology</i> , 2017 , 72, 171-174	10.2	28
671	Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. <i>European Journal of Cancer</i> , 2020 , 135, 203-210	7.5	28
670	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. <i>PLoS ONE</i> , 2015 , 10, e0139267	3.7	28
669	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
668	Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2012 , 107, 1009-16	8.7	28
667	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 555-563	8.7	28
666	Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 118, 1176-1178	8.7	28
665	IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma. <i>British Journal of Cancer</i> , 2015 , 112, 1190-8	8.7	27
664	Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. <i>European Urology</i> , 2015 , 68, 506-15	10.2	27
663	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series 2017 , 5, 66		27
662	Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014 , 16, 335	2.1	27
661	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017 , 72, 974-983	10.2	27

660	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 747-754	10.2	27
659	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 257-76	7	27
658	Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. <i>Annals of Oncology</i> , 2013 , 24, 2092-7	10.3	27
657	Utilization and expense of adjuvant cancer therapies following radical prostatectomy. <i>Cancer</i> , 2011 , 117, 4846-54	6.4	27
656	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2009 , 115, 2327-33	6.4	27
655	Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1837-40	9.7	27
654	Non-clear cell renal cancer: features and medical management. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 659-65	7.3	27
653	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4504-4504	2.2	27
652	Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020 , 38, 4240-4248	2.2	27
651	The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. <i>European Urology Focus</i> , 2019 , 5, 474-481	5.1	27
650	Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. <i>European Urology</i> , 2018 , 73, 445-451	10.2	27
649	Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation. <i>Journal of Urology</i> , 2017 , 198, 1061-1068	10.8	26
648	Variation in the use of active surveillance for low-risk prostate cancer. <i>Cancer</i> , 2018 , 124, 55-64	6.4	26
647	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 820-4	7.3	26
646	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 130-7	3.3	26
645	Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system. <i>BMJ Open</i> , 2014 , 4, e003921	3	26
644	ABO blood group and risk of renal cell cancer. <i>Cancer Epidemiology</i> , 2012 , 36, 528-32	2.8	26
643	Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. <i>British Journal of Cancer</i> , 2013 , 108, 2478-84	8.7	26

642	An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. <i>BJU International</i> , 2008 , 101, 712-5	5.6	26
641	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021 , 12, 808	17.4	26
640	Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2017 , 71, 714-718	10.2	25
639	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 136-45	7	25
638	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 118, 1238-1242	8.7	25
637	Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. <i>BJU International</i> , 2013 , 112, E273-80	5.6	25
636	A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2014 , 120, 1647-55	6.4	25
635	Recent advances in the systemic treatment of metastatic papillary renal cancer. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 373-9	3.5	25
634	Management of clinical stage I nonseminomatous germ cell testicular cancer. <i>Urologic Clinics of North America</i> , 2007 , 34, 137-48; abstract viii	2.9	25
633	Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4507-4507	2.2	25
632	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 724-732	3.3	24
631	The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. <i>Current Oncology Reports</i> , 2012 , 14, 295-306	6.3	24
630	Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. <i>Annals of Oncology</i> , 2013 , 24, 2927-8	10.3	24
629	Phenoxodiol: isoflavone analog with antineoplastic activity. <i>Current Oncology Reports</i> , 2006 , 8, 104-7	6.3	24
628	Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5012-5012	2.2	24
627	Asian Americans and prostate cancer: A nationwide population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 233.e7-15	2.8	24
626	Radiogenomics in renal cell carcinoma. <i>Abdominal Radiology</i> , 2019 , 44, 1990-1998	3	24
625	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019 , 15, 929-941	3.6	23

624	Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1439-1445	3.6	23
623	A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E93-4	3.3	23
622	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. <i>Cancer Cell</i> , 2020 , 38, 769-770	24.3	23
621	Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer</i> , 2016 , 122, 411-9	6.4	23
620	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021 , 4, e2021869	10.4	23
619	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology, The</i> , 2018 , 19, e317-e326	21.7	23
618	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018 , 24, 4399-4406	12.9	23
617	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015 , 26, 2392-8	10.3	22
616	Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. <i>Urology</i> , 2010 , 76, 1201-5	1.6	22
615	Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4514-4514	2.2	22
614	A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4598-TPS4598	2.2	22
613	Rethinking Clinical Trials Reform During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020 , 6, 1327-1329	13.4	22
612	Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer. <i>JCO Global Oncology</i> , 2020 , 6, 1248-1257	3.7	22
611	Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 652-660.e1	3.3	21
610	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , 2017 , 198, 817-823	2.5	21
609	Future directions and targeted therapies in bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 361-76, x	3.1	21
608	Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma. <i>Genetics in Medicine</i> , 2020 , 22, 1366-1373	8.1	21
607	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020 , 8, 1075-1084	12.5	21

606	Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis. <i>Cancer</i> , 2018 , 124, 925-933	6.4	21
605	Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 352-9	3.3	21
604	Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. <i>European Urology</i> , 2014 , 66, 1125-32	10.2	21
603	Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. <i>Journal of Urology</i> , 2009 , 181, 2470-5; discussion 2475	2.5	21
602	Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4507-4507	2.2	21
601	Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 889-90	59.2	21
600	The burden of skeletal-related events in patients with prostate cancer and bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 17.e9-17.e18	2.8	20
599	Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. <i>Thyroid</i> , 2018 , 28, 445-453	6.2	20
598	Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. <i>Journal of Urology</i> , 2016 , 195, 913-8	2.5	20
597	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e127-31	3.3	20
596	Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts. <i>Cancer</i> , 2012 , 118, 797-803	6.4	20
595	Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 354-8	3.3	20
594	Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 853-69	3.1	20
593	Differential expression of caveolin-1 in renal neoplasms. <i>Cancer</i> , 2007 , 110, 776-82	6.4	20
592	Evolving role of pegylated interferons in metastatic renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 823-9	3.5	20
591	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 71-90	7.3	20
590	Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4523-4523	2.2	20
589	Phase I/II study of the oral HIF-2 inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 611-611	2.2	20

588	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020 , 204, 1173-1179	2.5	20
587	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016 , 117, E20-3.6	3.6	19
586	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 504.e9-17	2.8	19
585	Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020 , 111, 907-923	6.9	19
584	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2020 , 78, 615-623	10.2	19
583	Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2018 , 200, 573-581	2.5	19
582	Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. <i>Thyroid</i> , 2018 , 28, 437-444	6.2	19
581	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019 , 15, 1683-1695	3.6	19
580	Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. <i>Urology</i> , 2013 , 81, 130-4	1.6	19
579	Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. <i>Future Oncology</i> , 2008 , 4, 85-92	3.6	19
578	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 548-548	2.2	19
577	Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 617-617	2.2	19
576	Determinants of cancer screening in Asian-Americans. <i>Cancer Causes and Control</i> , 2016 , 27, 989-98	2.8	19
575	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019 , 2, 643-648	6.7	19
574	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018 , 73, 262-270	10.2	18
573	MET as a target in papillary renal cell carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 3361-3	12.9	18
572	Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. <i>Journal of Urology</i> , 2012 , 187, 2068-73	2.5	18
571	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 1371-1380	12.9	18

570	Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 707-712	8.7	18
569	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020 , 3, e201839	10.4	17
568	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016 , 122, 3371-3377	6.4	17
567	Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 352-8	3.6	17
566	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy. <i>Cancer</i> , 2012 , 118, 365-70	6.4	17
565	Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients. <i>British Journal of Cancer</i> , 2014 , 110, 1433-7	8.7	17
564	Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. <i>Aging Male</i> , 2012 , 15, 34-41	2.1	17
563	Updates on novel therapies for metastatic renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 209-19	5.4	17
562	Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. <i>PLoS ONE</i> , 2014 , 9, e116101	3.7	17
561	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020 , 22, 709-718	8.1	17
560	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. <i>Annals of Surgical Oncology</i> , 2019 , 26, 297-305	3.1	17
559	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018 , 118, 1434-1441	8.7	17
558	Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. <i>Clinical Cancer Research</i> , 2018 , 24, 4081-4088	12.9	17
557	RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>American Journal of Roentgenology</i> , 2015 , 204, W282-8	5.4	16
556	LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. <i>Annals of Oncology</i> , 2020 , 31, S1201-S1202	10.3	16
555	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 495-500	3.3	16
554	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , 2014 , 9, 195-204	5	16
553	Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. <i>BJU International</i> , 2010 , 106, 979-85	5.6	16

552	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2081-90	2.5	16
551	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 410-410	2.2	16
550	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019 , 201, 735-741	2.5	16
549	Contemporary national trends in prostate cancer risk profile at diagnosis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 81-87	6.2	16
548	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019 , 27, 1589-1598	5.3	15
547	Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 221-229	3.3	15
546	Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. <i>European Journal of Cancer</i> , 2012 , 48, 1495-502	7.5	15
545	Recent advances in immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 997-1009	5.4	15
544	VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. <i>Current Clinical Pharmacology</i> , 2011 , 6, 164-8	2.5	15
543	Impact of body composition on clinical outcomes in metastatic renal cell cancer. <i>Oncologist</i> , 2011 , 16, 1484-6	5.7	15
542	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4518-4518	2.2	15
541	Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors. <i>PLoS ONE</i> , 2015 , 10, e0124711	3.7	15
540	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 102-111	6.7	15
539	A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5202-5211	12.9	14
538	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020 , 3, 530-539	6.7	14
537	The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. <i>European Journal of Cancer</i> , 2020 , 127, 118-122	7.5	14
536	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 57.e15-22	2.8	14
535	The impact of Medicare eligibility on cancer screening behaviors. <i>Preventive Medicine</i> , 2016 , 85, 47-52	4.3	14

534	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with 50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016 , 87, 125-32	1.6	14
533	Precision medicine for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 5-15	2.8	14
532	Weight gain on androgen deprivation therapy: which patients are at highest risk?. <i>Urology</i> , 2014 , 83, 1316-21	6.21	14
531	Use of surveillance imaging following treatment of small renal masses. <i>Journal of Urology</i> , 2013 , 190, 1680-5	2.5	14
530	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 120, 120-126	7	14
529	Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. <i>American Journal of Medicine</i> , 2015 , 128, 609-16	2.4	14
528	Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. <i>Urology</i> , 2015 , 85, 343-9	1.6	14
527	Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2014 , 20, 272-80	2.2	14
526	Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. <i>Journal of Urology</i> , 2012 , 188, 775-80	2.5	14
525	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4501-4501	2.2	14
524	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1049-1058	7.3	14
523	An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2019 , 24, 202-210	5.7	14
522	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021 , 127, 840-849	6.4	14
521	Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Current Oncology</i> , 2019 , 26, e175-e179	2.8	13
520	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 525-30.e1-3	3.3	13
519	Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. <i>Annals of Oncology</i> , 2018 , 29, 386-391	10.3	13
518	Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2503-2503	2.2	13
517	Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3036-3036	2.2	13

516	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , 2017 , 8, 103428-103436	3.3	13
515	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020 , 126, 1-10	7.5	13
514	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016 , 122, 402-10	6.4	13
513	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3725-3736	2.2	13
512	Non-clear cell renal cell carcinoma, part 2: therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 383-91	0.6	13
511	Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 403-410.e2	2.3	12
510	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 330.e19-25	2.8	12
509	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020 , 38, 761-766	24.3	12
508	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e961-e967	3.3	12
507	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1629-49	7.3	12
506	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>European Urology</i> , 2017 , 71, 970-978	10.2	12
505	Immunotherapy in the Elderly. <i>European Urology Focus</i> , 2017 , 3, 403-412	5.1	12
504	Incidence and determinants of 1-month mortality after cancer-directed surgery. <i>Annals of Oncology</i> , 2015 , 26, 399-406	10.3	12
503	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 900-5	2.8	12
502	Clinical treatment decisions for advanced renal cell cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 694-7	7.3	12
501	Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, e433-5	2.2	12
500	Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 364-364	2.2	12
499	Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4505-4505	2.2	12

498	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 467-467	2.2	12
497	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3009-3009	2.2	12
496	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4594-TPS4594	2.2	12
495	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights From Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020 , 3, 47-56	6.7	12
494	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. <i>Annals of Oncology</i> , 2020 , 31, S559-S560	10.3	12
493	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019 , 75, 35-41	10.2	12
492	Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19		12
491	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 238.e7-238.e17	2.8	11
490	Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. <i>Oncologist</i> , 2019 , 24, 1497-1501	5.7	11
489	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 395-8	3.3	11
488	Genomic investigation of etiologic heterogeneity: methodologic challenges. <i>BMC Medical Research Methodology</i> , 2014 , 14, 138	4.7	11
487	The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine. <i>British Journal of Cancer</i> , 2013 , 109, 2548-53	8.7	11
486	Everolimus- and temsirolimus-associated enteritis: report of three cases. <i>Journal of Clinical Oncology</i> , 2011 , 29, e404-6	2.2	11
485	Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4504-4504	2.2	11
484	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4599-TPS4599	2.2	11
483	Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 544-544	2.2	11
482	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021 , 79, 334-338	10.2	11
481	Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 497-506	2.7	11

480	Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-10	7.1	10
479	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016 , 15, 695-700	2.4	10
478	ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). <i>Prostate</i> , 2015 , 75, 1677-81	4.2	10
477	Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. <i>Annals of Oncology</i> , 2011 , 22, 245-7	10.3	10
476	Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. <i>Cancer</i> , 2010 , 116, 610-5	6.4	10
475	Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4500-4500	2.2	10
474	Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 579-579	2.2	10
473	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 304-313.e6	3.3	10
472	Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2926-2937	2.2	10
471	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 538-45	2.8	9
470	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 150-5	3.3	9
469	Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 71-9	3.3	9
468	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017 , 1, 41-47	0.6	9
467	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	9
466	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 421-8	7.3	9
465	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e299-305	3.3	9
464	Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. <i>Lancet Oncol</i> 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. <i>European Urology</i> , 2018 , 74, e139-e140	10.2	9
463	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018 , 36, 1767-1774	4	9

462	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma 2019 , 7, 289		9
461	Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 848-55	2.8	9
460	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 756-63	2.8	9
459	Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 79, 1318-22	4	9
458	Optimizing recent advances in metastatic renal cell carcinoma. <i>Current Oncology Reports</i> , 2009 , 11, 218-263		9
457	Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.. <i>Lancet Oncology</i> , 2022 ,	21.7	9
456	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4509-4509 ²	3.2	9
455	Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 482-482	2.2	9
454	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 413-413	2.2	9
453	Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 607-607	2.2	9
452	Results from a phase I expansion cohort of the first-in-class oral HIF-2 α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 558-558	2.2	9
451	Risk of dementia following androgen deprivation therapy for treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 410-418	6.2	9
450	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016 , 118, 279-85	5.6	9
449	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , 2016 , 122, 2389-98	6.4	9
448	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , 2016 , 2, 633-639	5.1	9
447	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 425-435.e4	3.3	9
446	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2021 , 26, 182-e361	5.7	9
445	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 338-343	4	8

444	709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study. <i>Annals of Oncology</i> , 2020 , 31, S558	10.3	8
443	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors 2020 , 8,		8
442	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018 , 131, 517-523	2.4	8
441	Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a Homozygous Deletion.. <i>JCO Precision Oncology</i> , 2017 , 1, 1-5	3.6	8
440	Identification of ALK gene alterations in urothelial carcinoma. <i>PLoS ONE</i> , 2014 , 9, e103325	3.7	8
439	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 262-9	3.3	8
438	Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5027-5027	2.2	8
437	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4576-TPS4576	2.2	8
436	Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4580-TPS4580	2.2	8
435	Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 514-514	2.2	8
434	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 545-545	2.2	8
433	Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4518-4518	2.2	8
432	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4583-4583	2.2	8
431	The evolving landscape of metastatic renal cell carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 299-302	7.1	8
430	Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2134330	10.4	8
429	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.. <i>Lancet Oncology, The</i> , 2021 ,	21.7	8
428	Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance). <i>Cancer</i> , 2020 , 126, 5311-5318	6.4	8
427	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma 2020 , 8,		8

426	Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC 2021 , 9,		8
425	CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial. <i>Annals of Oncology</i> , 2016 , 27, vi566	10.3	8
424	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma 2016 , 4, 26		8
423	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	8
422	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , 2018 , 14, e1007679	6	8
421	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021 , 108, 106482	2.3	8
420	Non-clear cell renal cell carcinoma, part 1: histology. <i>Clinical Advances in Hematology and Oncology</i> , 2015 , 13, 308-13	0.6	8
419	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 563-569.e3	3.3	7
418	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 251-63	7	7
417	Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 503.e7-15	2.8	7
416	Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective. <i>Surgical Pathology Clinics</i> , 2015 , 8, 657-62	3.9	7
415	LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). <i>Annals of Oncology</i> , 2020 , 31, S1202-S1203	10.3	7
414	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e327-e333	3.3	7
413	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. <i>British Journal of Cancer</i> , 2016 , 115, 12-9	8.7	7
412	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 335-40	3.3	7
411	Renal-cell carcinoma: a step closer to a new classification. <i>Lancet Oncology, The</i> , 2013 , 14, 105-7	21.7	7
410	An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer. <i>BJU International</i> , 2015 , 116, 911-9	5.6	7
409	Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. <i>British Journal of Haematology</i> , 2003 , 123, 959	4.5	7

408	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 396-396	2.2	7
407	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 426-426	2.2	7
406	Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 499-499	2.2	7
405	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4596-TPS4596	2.2	7
404	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS706-TPS706	2.2	7
403	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 690-696	6.1	7
402	Kidney cancer: Recurrence in renal cell carcinoma: the work is not done. <i>Nature Reviews Urology</i> , 2016 , 13, 246-7	5.5	7
401	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020 , 126, 73-82	5.6	7
400	Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	7
399	Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 290-290	2.2	7
398	Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study 2020 , 8,		6
397	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). <i>Kidney Cancer</i> , 2018 , 2, 31-36	0.6	6
396	Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e1060-e1068	3.3	6
395	The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE Military Database. <i>Journal of Urology</i> , 2017 , 198, 1295-1300	2.5	6
394	Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. <i>Clinical Genitourinary Cancer</i> , 2008 , 6, 15-20	3.3	6
393	A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 355-355	2.2	6
392	Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 372-372	2.2	6
391	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 398-398	2.2	6

390	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4571-TPS4571	2.2	6
389	Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4558-4558	2.2	6
388	A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 436-436	2.2	6
387	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 435-435	2.2	6
386	Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021 ,	13.4	6
385	Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. <i>Annals of Internal Medicine</i> , 2020 , 173, 368-374	8	6
384	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2021 , 7, 773-775	13.4	6
383	Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4025-4035	13.9	6
382	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021 , 12, 820-826	3.6	6
381	Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 65-71	3.3	6
380	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019 , 125, 1319-1329	6.4	6
379	Use of Preventive Health Services Among Cancer Survivors in the U.S. <i>American Journal of Preventive Medicine</i> , 2018 , 55, 830-838	6.1	6
378	Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). <i>Annals of Oncology</i> , 2018 , 29, viii311	10.3	6
377	Metabolic reprogramming in renal cancer: Events of a metabolic disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021 , 1876, 188559	11.2	6
376	Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	6
375	Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz003	4.6	5
374	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 593-599	6.2	5
373	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 250-6	3.3	5

372	Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis. <i>JAMA Oncology</i> , 2016 , 2, 543-5	13.4	5
371	Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2013 , 12, 415-21	2.4	5
370	New therapies for castrate-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2069-74	4.7	5
369	Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4505-4505	2.2	5
368	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 387-387	2.2	5
367	Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 351-351	2.2	5
366	PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4585-4585	2.2	5
365	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4530-4530	2.2	5
364	Pembrolizumab (pembro) versus investigator choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4521-4521	2.2	5
363	Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 582-582	2.2	5
362	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4514-4514	2.2	5
361	Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 566-566	2.2	5
360	Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 608-608	2.2	5
359	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. <i>JAMA Oncology</i> , 2020 , 6, 133-141	13.4	5
358	Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 464-470	2.2	5
357	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , 2021 , 145, 1-10	7.5	5
356	Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e92-e99	3.3	5
355	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. <i>European Urology Oncology</i> , 2021 , 4, 893-893	6.7	5

354	Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 310-310	2.2	5
353	Care without a compass: Including patients with cancer in COVID-19 studies. <i>Cancer Cell</i> , 2021 , 39, 895-896	4.3	5
352	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. <i>European Journal of Cancer</i> , 2021 , 151, 115-125	7.5	5
351	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.. <i>British Journal of Cancer</i> , 2021 ,	8.7	5
350	Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 82-84	19.4	4
349	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e598-e609	3.3	4
348	Response of Primary Renal Cell Carcinoma to Systemic Therapy. <i>European Urology</i> , 2019 , 76, 852-860	10.2	4
347	Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013 , 27, 1261-83, ix	3.1	4
346	Sunitinib in renal-cell carcinoma: expanded indications. <i>Lancet Oncology, The</i> , 2009 , 10, 740	21.7	4
345	The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 698-9		4
344	Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. <i>American Journal of Medicine</i> , 2002 , 113, 700-1	2.4	4
343	Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 416-416	2.2	4
342	cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 487-487	2.2	4
341	A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2506-2506	2.2	4
340	Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3013-3013	2.2	4
339	Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3016-3016	2.2	4
338	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS42-TPS42	2.2	4
337	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS712-TPS712	2.2	4

336	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 103-103	2.2	4
335	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4568-4568	2.2	4
334	PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4596-TPS4596	2.2	4
333	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 584-584	2.2	4
332	CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS682-TPS682	2.2	4
331	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS684-TPS684	2.2	4
330	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2021 , 81, 266-266	10.2	4
329	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
328	Why shouldn't we use warfarin alone to treat acute venous thrombosis?. <i>Cleveland Clinic Journal of Medicine</i> , 2002 , 69, 546-8	2.8	4
327	Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. <i>Journal of Urology</i> , 2019 , 201, 728-734	2.5	4
326	OncoAlert Round Table Discussions: The Global COVID-19 Experience. <i>JCO Global Oncology</i> , 2021 , 7, 455-463	3.7	4
325	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. <i>ESMO Open</i> , 2021 , 6, 100101	6	4
324	Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors. <i>International Journal of Cancer</i> , 2021 , 149, 1455-1462	7.5	4
323	Data on Medicare eligibility and cancer screening utilization. <i>Data in Brief</i> , 2016 , 7, 679-81	1.2	4
322	A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. <i>Investigational New Drugs</i> , 2021 , 39, 1019-1027	4.3	4
321	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 341-348	3.3	4
320	Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021 , 39, 1042-1044	24.3	4
319	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021 , 10, 1212-1221	4.8	4

318	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e224304	10.4	4
317	Risk Assessment in Small Renal Masses: A Review Article. <i>Urologic Clinics of North America</i> , 2017 , 44, 189-202	3.3	3
316	Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF-directed Therapy. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 396-402	3.3	3
315	Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e1089-e1094	3.3	3
314	The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 443-450.e1	3.3	3
313	Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial. <i>Annals of Oncology</i> , 2017 , 28, v623	10.3	3
312	Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 679-80	19.4	3
311	Integrative clinical and molecular characterization of translocation renal cell carcinoma.. <i>Cell Reports</i> , 2022 , 38, 110190	10.6	3
310	Soluble PD-L1 as an early marker of progressive disease on nivolumab. 2022 , 10,		3
309	A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 353-353	2.2	3
308	Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4503-4503	2.2	3
307	The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4593-TPS4593	2.2	3
306	PD-L1 expression in non-clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 424-424	2.2	3
305	Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 437-437	2.2	3
304	Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 470-470	2.2	3
303	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4524-4524	2.2	3
302	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4557-4557	2.2	3
301	Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4517-4517	2.2	3

300	A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS4595-TPS4595	2.2	3
299	Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4516-4516	2.2	3
298	Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4556-4556	2.2	3
297	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 581-581	2.2	3
296	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS4597-TPS4597	2.2	3
295	Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 652-652	2.2	3
294	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 653-653	2.2	3
293	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5063-5063	2.2	3
292	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19321-e19321	2.2	3
291	The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.. <i>ESMO Open</i> , 2021 , 7, 100339	6	3
290	PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma		3
289	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5598-5608	12.9	3
288	Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S. <i>Oncologist</i> , 2021 , 26, e905-e906	5.7	3
287	Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4561-4561	2.2	3
286	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4807-4813	12.9	3
285	State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. <i>European Urology Focus</i> , 2020 , 6, 37-40	5.1	3
284	Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2021 , 27, 2087-2099	12.9	3
283	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. <i>Cell Reports</i> , 2021 , 34, 108926	10.6	3

282	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021 , 21, 904	4.8	3
281	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2020 , 38, 1807-1814	4.3	2
280	Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts. <i>JCO Global Oncology</i> , 2020 , 6, 293-306	3.7	2
279	The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 1168-70	7.3	2
278	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 185-92	3.3	2
277	Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007. <i>European Urology Supplements</i> , 2008 , 7, 494-507	0.9	2
276	Anti-CAIX BB[CAR4/8 T]cells exhibit superior efficacy in a ccRCC mouse model.. <i>Molecular Therapy - Oncolytics</i> , 2022 , 24, 385-399	6.4	2
275	Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 352-352	2.2	2
274	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 301-301	2.2	2
273	Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4510-4510	2.2	2
272	PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4552-4552	2.2	2
271	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4576-4576	2.2	2
270	Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4508-4508	2.2	2
269	A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4559-4559	2.2	2
268	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 408-408	2.2	2
267	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 430-430	2.2	2
266	Can pelvic lymph node dissection be omitted in intermediate-risk prostate cancer patients? A SEER-based comparative study using inverse-probability-of-treatment weighting.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 95-95	2.2	2
265	Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2565-2565	2.2	2

264	Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4540-4540 ^{2,2}	2
263	Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 570-570	2.2 2
262	Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 73-73	2.2 2
261	Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4579-4579	2.2 2
260	Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4600-TPS4600 ^{2,2}	2
259	Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 453-453	2.2 2
258	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 615-615	2.2 2
257	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 619-619 ^{2,2}	2
256	Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 639-639	2.2 2
255	Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1528-1528	2.2 2
254	Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4515-4515	2.2 2
253	Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 550-550	2.2 2
252	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5010-5010	2.2 2
251	Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 690-690	2.2 2
250	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 715-715	2.2 2
249	Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 728-728	2.2 2
248	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 684-684	2.2 2
247	JAVELIN: avelumab another spear to fight urothelial carcinoma. <i>Lancet Oncology, The</i> , 2018 , 19, 5-7	21.7 2

246	Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma		2
245	A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4594-TPS4594	2.2	2
244	Dissecting the immunogenomic biology of cancer for biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 133-134	19.4	2
243	Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-11	7.1	2
242	Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database. <i>Journal of Global Oncology</i> , 2018 , 4, 1-14	2.6	2
241	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. <i>Annals of Oncology</i> , 2019 , 30, viii315	10.3	2
240	Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2018 , 2, 37-46	0.6	2
239	Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. <i>Annals of Oncology</i> , 2018 , 29, viii308	10.3	2
238	Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 385, 287	59.2	2
237	Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e306-e312	3.3	2
236	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 352-352	2.2	2
235	Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset.. <i>Nature Communications</i> , 2021 , 12, 7304	17.4	2
234	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	2
233	Reply to B. Rini et al and S. Buti et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1859-1860	2.2	1
232	Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	1
231	MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES. <i>Journal of Urology</i> , 2014 , 191,	2.5	1
230	Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 266-70	6.2	1
229	MP86-17 THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA. <i>Journal of Urology</i> , 2017 , 197,	2.5	1

228	Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab 2015 , 3,		1
227	18 F-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy. <i>BJU International</i> , 2010 , 106, 1249-50 ^{5,6}		1
226	Risk of bleeding not increased by sorafenib or sunitinib [Authors' reply. <i>Lancet Oncology, The</i> , 2010 , 11, 113	21.7	1
225	Metastatic renal cell carcinoma: A guide to therapy based on current evidence. <i>Urology Annals</i> , 2009 , 1, 9	1	1
224	Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
223	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4525-4525	2.2	1
222	FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4577-4577	2.2	1
221	A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4686-TPS4686	2.2	1
220	Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 161-161	2.2	1
219	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 394-394	2.2	1
218	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 398-398	2.2	1
217	First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 430-430	2.2	1
216	CGH array and matching gene expression profiling for identification of distinct molecular variants among type II papillary renal cell carcinomas.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4527-4527	2.2	1
215	Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 334-334	2.2	1
214	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 336-336	2.2	1
213	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 353-353	2.2	1
212	Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 395-395	2.2	1
211	ABO blood group and risk of lethal prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 69-69	2.2	1

210	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4519-4519	2.2	1
209	Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4564-4564	2.2	1
208	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 311-311	2.2	1
207	miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 364-364	2.2	1
206	Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 404-404	2.2	1
205	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 405-405	2.2	1
204	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 422-422	2.2	1
203	Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 433-433	2.2	1
202	Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 464-464	2.2	1
201	Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4506-4506	2.2	1
200	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4570-4570	2.2	1
199	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23221-e23221	2.2	1
198	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-501	2.2	1
197	Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4572-4572	2.2	1
196	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4573-4573 ¹	2.2	1
195	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4585-4585	2.2	1
194	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 346-346	2.2	1
193	ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18690-e18690	2.2	1

192	Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 230-230	2.2	1
191	The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 279-279	2.2	1
190	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 451-451	2.2	1
189	CD73 expression in primary and metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 643-643	2.2	1
188	Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 645-645 ²	2.2	1
187	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS710-TPS710	2.2	1
186	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 740-740	2.2	1
185	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.. <i>BJUI Compass</i> , 2022 , 3, 169-172	0.9	1
184	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. <i>JAMA Network Open</i> , 2022 , 5, e2142046	10.4	1
183	Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. <i>European Journal of Medical Genetics</i> , 2021 , 64, 104359	2.6	1
182	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 634-634	2.2	1
181	HIF-2 α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma		1
180	First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4577-4577	2.2	1
179	Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury.. <i>Kidney360</i> , 2021 , 2, 205-214	1.8	1
178	PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4526-4526	2.2	1
177	Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4521-4521	2.2	1
176	Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4578-4578	2.2	1
175	Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11546-11546	2.2	1

174	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 353-353	2.2	1
173	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020 , 4, 29-39	0.6	1
172	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e350-e359	3.3	1
171	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 735.e9-735.e15	2.8	1
170	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). <i>Oncologist</i> , 2021 , 26, 560-e1103	5.7	1
169	Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. <i>Cancer Discovery</i> , 2021 , 11, 1330-1335	24.4	1
168	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4596-TPS4596	2.2	1
167	Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4548-4548	2.2	1
166	Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4578-4578	2.2	1
165	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021 , 79, 665-673	10.2	1
164	Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4514-4514	2.2	1
163	PD04-05 TRENDS OF METASTASECTOMY FOR METASTATIC RENAL CELL CARCINOMA AND THEIR IMPACT ON OVERALL SURVIVAL. <i>Journal of Urology</i> , 2016 , 195,	2.5	1
162	Impact of Prior Platinum-Based Therapy on Patients Receiving Salvage Systemic Treatment for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 494-498	3.3	1
161	Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial. <i>Kidney Cancer</i> , 2019 , 3, 241-251	0.6	1
160	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 130.e17-130.e24	2.8	1
159	Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 472-472	2.2	1
158	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018 ;73:262-70. <i>European Urology</i> , 2018 , 73, e100-e101	10.2	1
157	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1

156	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 400.e15-400.e22 ¹	2.8	1
155	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021 , 108, 106481	2.3	1
154	Neurotoxicities of novel non-steroidal anti-androgens for prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 166, 103463	7	1
153	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. <i>Lung Cancer</i> , 2021 , 160, 78-83	5.9	1
152	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 157, 50-58	7.5	1
151	Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 334-334	2.2	1
150	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100448	3.6	1
149	TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 786-795	2.2	1
148	Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101806	2.2	1
147	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
146	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
145	COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO CoCARE). <i>ESMO Open</i> , 2022 , 100499	6	1
144	Uncommon Tumors of the Kidney 2017 , 19-40		0
143	Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4582-4582	2.2	0
142	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 626-626	2.2	0
141	Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3052-3052	2.2	0
140	Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5077-5077	2.2	0
139	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15578-e15578	2.2	0

138	The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 552-552	2.2	0
137	Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4592-TPS4592 ^{2,2}	2.2	0
136	Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4554-4554	2.2	0
135	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021 , 258-259, 61-68	2.3	0
134	Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 343-343	2.2	0
133	First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 317-317	2.2	0
132	Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 323-323	2.2	0
131	Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 308-308	2.2	0
130	Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac037	1	0
129	Reply to Roberto Iacovelli, Walter Artibani, and Giampaolo Tortora's Letter to the Editor re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. <i>Eur Urol</i> 2017;71:970-8. <i>European Urology</i> , 2017 , 71, e177-e178	10.2	
128	Reply to C. Buttigliero et al and B. Biswas et al. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1266-1267	2.2	
127	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns' Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018 , 73, e96-e97	10.2	
126	In Reply. <i>Oncologist</i> , 2017 , 22, 1561	5.7	
125	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4171-2	2.2	
124	Reply to impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. <i>Cancer</i> , 2011 , 117, 656-656	6.4	
123	Reply to D.R. Minor. <i>Journal of Clinical Oncology</i> , 2010 , 28, e620-e620	2.2	
122	Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 698-698	2.2	
121	Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2021 , 1-6	3.2	

- 120 Statin use and risk of renal cell carcinoma in three prospective cohort studies.. *Journal of Clinical Oncology*, **2018**, 36, 679-679 2.2
- 119 Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 78-78 2.2
- 118 Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9-10 prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 23-23 2.2
- 117 Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. *Journal of Clinical Oncology*, **2018**, 36, 667-667 2.2
- 116 FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. *Journal of Clinical Oncology*, **2018**, 36, 465-465 2.2
- 115 The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. *Journal of Clinical Oncology*, **2018**, 36, 492-492 2.2
- 114 Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer.. *Journal of Clinical Oncology*, **2018**, 36, 59-59 2.2
- 113 Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis.. *Journal of Clinical Oncology*, **2018**, 36, 629-629 2.2
- 112 Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. *Journal of Clinical Oncology*, **2018**, 36, 4539-4539 2.2
- 111 PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. *Journal of Clinical Oncology*, **2018**, 36, TPS4597-TPS4597 2.2
- 110 Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. *Journal of Clinical Oncology*, **2018**, 36, e17041-e17041 2.2
- 109 Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel.. *Journal of Clinical Oncology*, **2018**, 36, e17027-e17027 2.2
- 108 Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.. *Journal of Clinical Oncology*, **2018**, 36, 3036-3036 2.2
- 107 Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2018**, 36, e16554-e16554 2.2
- 106 Comprehensive genomic characterization of urothelial carcinomas.. *Journal of Clinical Oncology*, **2018**, 36, 4527-4527 2.2
- 105 Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2019**, 37, 66-66 2.2
- 104 Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC).. *Journal of Clinical Oncology*, **2019**, 37, 664-664 2.2
- 103 Hyperprogressive disease on immune checkpoint therapy in advanced solid malignancies: A systematic review.. *Journal of Clinical Oncology*, **2019**, 37, 154-154 2.2

102	Germline alterations in urothelial carcinoma (UC) patients with family history of UC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 474-474	2.2
101	Cell-free DNA analysis in renal cell carcinoma: Comparison with tumor sequencing and correlation with response to therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 655-655	2.2
100	Genomic profiling of variant urinary tract tumor histologies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 450-450	2.2
99	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 454-454	2.2
98	Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4571-4571	2.2
97	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4582-4582	2.2
96	Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4578-4578	2.2
95	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. <i>Journal of Medical Internet Research</i> , 2019 , 21, e12044	7.6
94	Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5070-5070	2.2
93	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5046-5046	2.2
92	Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9639-9639	2.2
91	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5091-5091	2.2
90	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4514-4514	2.2
89	Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15558-e15558	2.2
88	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13547-e13547	2.2
87	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13502-e13502	2.2
86	A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4570-4570	2.2
85	Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma 2015 , 555-567	

84	The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 414-414	2.2
83	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 32-32	2.2
82	Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 365-365	2.2
81	Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 435-435	2.2
80	Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 456-456	2.2
79	Genomic landscape of high-grade T1 micropapillary bladder tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 299-299	2.2
78	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum-based chemotherapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 351-351	2.2
77	Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 406-406	2.2
76	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 369-369	2.2
75	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 34-34	2.2
74	Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4530-4530	2.2
73	Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4527-4527	2.2
72	Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15518-e15518	2.2
71	Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15520-e15520	2.2
70	Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4520-4520	2.2
69	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4560-4560	2.2
68	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15583-e15583	2.2
67	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15519-e15519	2.2

66	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e17528-e17528	2.2
65	Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 363-363	2.2
64	Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 588-588	2.2
63	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 54-54	2.2
62	Assessment of metastasectomy complications in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 619-619	2.2
61	Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 450-450	2.2
60	Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 431-431	2.2
59	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 386-386	2.2
58	Characterization of mutational load in patients with advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 460-460	2.2
57	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 616-616	2.2
56	The impact of weight change during treatment with targeted therapy in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 557-557	2.2
55	Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 620-620	2.2
54	Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 534-534	2.2
53	Impact of metformin on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 531-531	2.2
52	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 33-33	2.2
51	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 442-442	2.2
50	The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 304-304	2.2
49	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 503-503	2.2

- 48 Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. *Journal of Clinical Oncology*, **2016**, 34, 4554-4554 2.2
- 47 Virtual consults: A paradigm shift for second opinions in oncology care.. *Journal of Clinical Oncology*, **2016**, 34, e18049-e18049 2.2
- 46 First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. *Journal of Clinical Oncology*, **2016**, 34, 4510-4510 2.2
- 45 Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers.. *Journal of Clinical Oncology*, **2016**, 34, 4573-4573 2.2
- 44 Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. *Journal of Clinical Oncology*, **2016**, 34, 4535-4535 2.2
- 43 Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.. *Journal of Clinical Oncology*, **2016**, 34, 3068-3068 2.2
- 42 Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles.. *Journal of Clinical Oncology*, **2016**, 34, 4541-4541 2.2
- 41 Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2017**, 35, 4570-4570 2.2
- 40 Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.. *Journal of Clinical Oncology*, **2017**, 35, 4583-4583 2.2
- 39 Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. *Journal of Clinical Oncology*, **2017**, 35, e16065-e16065 2.2
- 38 Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. *Journal of Clinical Oncology*, **2017**, 35, 4580-4580 2.2
- 37 Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. *Journal of Clinical Oncology*, **2017**, 35, e16012-e16012 2.2
- 36 Cancer of the Genitourinary Tract **2010**, 233-277
- 35 VEGF inhibitors **2011**, 28-41
- 34 Management of Biochemical Recurrence After Localized Treatment for Prostate Cancer **2012**, 347-359
- 33 Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine.. *Journal of Clinical Oncology*, **2012**, 30, e15007-e15007 2.2
- 32 Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, e21016-e21016 2.2
- 31 Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy.. *Journal of Clinical Oncology*, **2013**, 31, 283-283 2.2

30	Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 23-23	2.2
29	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 270-270	2.2
28	Metastatic nonclear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 396-396	2.2
27	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 347-347	2.2
26	Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 432-432	2.2
25	Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 330-330	2.2
24	Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer patients in an academic setting.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 224-224	2.2
23	Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 411-411	2.2
22	Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 409-409	2.2
21	Improving tumor mutational burden calibration in non-European patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1559-1559	2.2
20	Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4529-4529	2.2
19	Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4547-4547	2.2
18	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10536-10536	2.2
17	The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4552-4552	2.2
16	Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4547-4547	2.2
15	Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4583-4583	2.2
14	Automated identification of immune related adverse events in oncology patients using machine learning.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1551-1551	2.2
13	A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS4593-TPS4593	2.2

12	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 354-354	2.2
11	Sequential Response to Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With Fusion-Positive Metastatic Urothelial Carcinoma. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6
10	B2B: Kidney Cancer Summary. <i>Société Internationale Dfurologie Journal</i> , 2021 , 2, S19-S28	0.1
9	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 912-920	5.2
8	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 569-569	2.2
7	Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 381-381	2.2
6	Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 390-390	2.2
5	Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 310-310	2.2
4	Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 281-281	2.2
3	FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 549-549	2.2
2	Patient-reported outcomes: what really matters to patients? - Authors' reply.. <i>Lancet Oncology, The</i> , 2022 , 23, e199	21.7
1	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. <i>European Journal of Cancer</i> , 2022 , 170, 158-168	7.5